BMS Signs a Clinical Trial Collaboration with UbiVac to Evaluate the Triplet Therapy for Advanced Triple Negative Breast Cancer
Shots:
- The two companies collaborated to evaluate the safety- tolerability- and preliminary efficacy of UbiVac’s DPV-00 in combination with BMS’ anti-OX40 (BMS-986178) combined with Opdivo (nivolumab)
- The P-Ib study will test the hypothesis that combination immunotherapy with the DPV-001 vaccine and anti-OX40 will boost anticancer immunity in patients with advanced TNBC
- UbiVac’s DRibble Platform Vaccine- DPV-001 contains 100+ proteins overexpressed by the average TNBC and as many as 1-700 altered peptide ligands that can enhance immunity against cancer antigens
Click here to read full press release/ article
Ref: BusinessWire | Image: BMS
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com